DOPAR
LOE ApproachingNDAORALTABLET
Approved
Jun 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DOPAR is an oral tablet containing levodopa, a dopamine precursor approved in 1970 for Parkinson's Disease. It crosses the blood-brain barrier and is converted to dopamine in the brain to relieve motor symptoms. The drug represents a foundational pharmacotherapy for this chronic neurodegenerative condition.
LOE Approaching
As an LOE-approaching product with modest competitive pressure (30%), the brand team is likely focused on lifecycle extension and managed decline rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Efficacy and Safety of Entacapone Combined With Madopar in the Treatment of Early Parkinson's Disease: An Observational, Multicenter, Case-Control Study
Started Jun 2025
216 enrolled
Parkinson Disease (PD)
Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome
Started Feb 2003
58 enrolled
Restless Legs Syndrome
Career Relevance
Working on DOPAR offers mid-to-senior career opportunities focused on lifecycle management, regulatory compliance, and operational optimization in a stable therapeutic area. This is ideal for professionals seeking established product stewardship roles rather than high-growth innovation positions, with emphasis on cross-functional leadership and efficiency.
Worked on DOPAR at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.